title: Anti-hepato-cytotoxic serum treatment results in acute liver failure.
abstract: Only few conditions in medicine are more dramatic or more devastating than acute liver failure, severe liver-cell dysfunction strikes previously well people suddenly, and many of them die. Acute liver failure (ALF) is broad term that refers to both fulminant hepatic failure (FHF) and sub-fulminant hepatic failure (or late-onset hepatic failure). FHF may result from a variety of hepatic disease processes. Viral hepatitis and hepatotoxic drugs are the most common factors inducing severe illness with the loss of hepatic function. Elevated serum concentrations of bacterial endotoxin, tumor necrosis factor-a, and interleukin-1 and interleukin-6 have been found in FHF, but the specific roles of these inflammatory factors are unclear. Numerous causes of FHF exist, but viral hepatitis and acetaminophen overdoses are the most common. The cause remains unknown in as many as 15% of patients. The aim of the study was the evaluation of the clinical course and complications of acute liver failure in experiment, We created an experimental model using hepatotoxic substance (CCL4), which causes centrilobular lesions in liver parenchyma. Nowadays, total or subtotal liver transplantation supposed to be an effective method. The restrictions of this method includes: 1. Donor organ deficit, 2. Post-operative complications, 3. Lifetime immunosuppression, 4. Expensiveness of the method. Our method proposes treatment by anti-hepato-cytotoxic serum, which induces stimulation of hepatocyte regeneration. It consists of vasoactive mediators (nitric oxide, carbon monoxide), activated complement cascade components, immunomodulators, regenerative hepatocytes, membrano-protectors and hepato-stimulator medications.
authors.affiliation: Department of Clinical Anatomy, Anesthesiology, Reanimatology and Toxicology, Georgian State Medical Academy.
authors.forename: D
authors.initials: D
authors.lastname: Topuria
authors.forename: Z
authors.initials: Z
authors.lastname: Kakabadze
authors.forename: N
authors.initials: N
authors.lastname: Lobdjanidze
authors.forename: N
authors.initials: N
authors.lastname: Chavchanidze
mesh_terms: D000818:Animals; D016913:Blood Component Transfusion / Q000379:methods*; D002251:Carbon Tetrachloride / Q000633:toxicity; D004195:Disease Models, Animal; D017114:Liver Failure, Acute / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D044967:Serum; D016896:Treatment Outcome
chemical_list: D002251:Carbon Tetrachloride